Floatz logo

Crte7A2-01 Tcr-T Cell Therapy

Other Solid Tumors

Corregene Biotechnology Co., LtdCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Other Solid Tumors cohort.

Asset / SponsorPhaseRating
Epirubicin
Karyopharm Therapeutics Inc
Phase 1/2B
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
Memorial Sloan Kettering Cancer Center
Phase 2B
Cyclophosphamide
National University Hospital, Singapore
Phase 1/2B
Pembrolizumab
Evopoint Biosciences Inc.
Phase 1/2B
Fludarabine
National University Hospital, Singapore
Phase 1/2CCC

View all 46 →

Same molecule, other indications

Crte7A2-01 Tcr-T Cell Therapy is also rated in:

head and neck cancerDormant
CC
Indicative ·
43 / 100
View asset →
anal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
cervical cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →